Elias Aboujaoude, MD, MA

Clinical Focus

• Psychiatry
• OCD, impulse control disorders, anxiety disorders

Professional Education

• Board Certification: Psychiatry, American Board of Psychiatry and Neurology (2004)
• SUMC - Graduate Medical Education (2002) CA
• UCSF Medical Center (1999) CA
• Stanford University School of Medicine (1998) CA

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. 

• Consulting: Peer Group, Rx Diaglogue, Jazz Pharmaceuticals, Forest Labs

Clinical Trials

• Duloxetine for the Treatment of Dysthymia Completed
• Memantine Augmentation in Obsessive-Compulsive Disorder Completed
• Study of SEP-225441 in Subjects with Generalized Anxiety Disorder No longer recruiting

Publications

• Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Aboujaoude E,  Barry JJ, Gamel N.  J Clin Psychopharmacol.  2009; 29 (1): 51-5
• Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Koran LM,  Aboujaoude E, Gamel NN.  J Clin Psychiatry.  2009;
• Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. Koran LM,  Aboujaoude EN, Gamel NN.  J Clin Psychiatry.  2007; 68 (3): 422-7
• Duloxetine treatment of dysthymia and double depression: an open-label trial. Koran LM,  Aboujaoude EN, Gamel NN.  J Clin Psychiatry.  2007; 68 (5): 761-5
• Estimated prevalence of compulsive buying behavior in the United States. Koran LM,  Faber RJ, Aboujaoude E, Large MD, Serpe RT.  Am J Psychiatry.  2006; 163 (10): 1806-12
• Potential markers for problematic internet use: a telephone survey of 2,513 adults. Aboujaoude E,  Koran LM, Gamel N, Large MD, Serpe RT.  CNS Spectr.  2006; 11 (10): 750-5
• Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. Koran LM,  Aboujaoude E, Ward H, Shapira NA, Sallee FR, Gamel N, Elliott M.  J Clin Psychopharmacol.  2006; 26 (1): 79-83
• Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. Koran LM,  Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M.  J Clin Psychiatry.  2005; 66 (3): 353-9
• Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. Koran LM,  Gamel NN, Choung HW, Smith EH, Aboujaoude EN.  J Clin Psychiatry.  2005; 66 (4): 515-20
• Overview of Kleptomania and Phenomenological Description of 40 Patients. Aboujaoude E,  Gamel N, Koran LM.  Prim Care Companion J Clin Psychiatry.  2004; 6 (6): 244-247
• A case of kleptomania correlating with premenstrual dysphoria. Aboujaoude E,  Gamel N, Koran LM.  J Clin Psychiatry.  2004; 65 (5): 725-6
• A 1-year naturalistic follow-up of patients with compulsive shopping disorder. Aboujaoude E,  Gamel N, Koran LM.  J Clin Psychiatry.  2003; 64 (8): 946-50
• The Psychiatric Hospital of the Cross: a sane asylum in the Middle East. Aboujaoude E,  Am J Psychiatry.  2002; 159 (12): 1982
• Assays of oxidative DNA damage biomarkers 8-oxo-2'-deoxyguanosine and 8-oxoguanine in nuclear DNA and biological fluids by high-performance liquid chromatography with electrochemical detection. Shigenaga MK,  Aboujaoude EN, Chen Q, Ames BN.  Methods Enzymol.  1994; 234 16-33